Premium
HCV viremic donors with hepatic bridging fibrosis: Are we ready to use their livers in the era of direct‐acting antivirals?
Author(s) -
Martini S.,
David E.,
Tandoi F.,
Dell Olio D.,
Salizzoni M.,
Saracco G.M.,
Romagnoli R.
Publication year - 2017
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.14447
Subject(s) - medicine , liver transplantation , hepatitis c , transplantation , scopus , consensus conference , hepatitis c virus , organ transplantation , immunology , medline , virus , law , political science
We read with interest the report from the American Society of Transplantation Consensus Conference on the use of hepatitis C (HCV) viremic donors in solid organ transplantation, which took place in Dallas in January 2017 (1). In the interferon-era, liver grafts from HCV-positive donors with no more than periportal fibrosis (F2 Ishak) did not show an outcome disadvantage compared with HCV-negative ones (2,3). In U.S., 16.9% of HCV-positive cirrhotics currently receive an organ from HCV-positive donors, 50% of whom are viremic and expected to transmit the infection (1). Considering the gap between organ demand and supply, the meeting participants felt that the availability of safe and effective direct-acting antivirals (DAAs) makes expansion of the criteria for transplanting HCV viremic organs into non-viremic recipients a possibility (1). This article is protected by copyright. All rights reserved.